Cellanome
Cellanome is a private biotech that sells the R3200 Platform—an integrated system combining proprietary CellCage™ hydrogel enclosures, live-cell imaging, and single-cell transcriptomics—to academic labs and biopharmaceutical companies for multimodal cell analysis across immunology, oncology, neurobiology, and aging research.
- Company typePrivate
- Founded2020
- HeadquartersRedwood City, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cellanome does
Cellanome is a private biotechnology company founded in 2020 that has developed the R3200 Platform, an integrated live-cell analysis system combining proprietary CellCage™ photopatterning, automated fluorescent and brightfield imaging, and single-cell transcriptomics into a single workflow. The platform is designed to address a fragmentation problem in cell biology, where traditional tools force researchers to choose between observing live-cell behavior and capturing molecular state. CellCage™ enclosures—biocompatible hydrogel microenvironments formed via digital micromirror device photopatterning in 2-3 seconds per image—keep cells viable, attached, and trackable for days to weeks, supporting 5,000+ parallel enclosures per lane. The Perturb-LINK methodology enables phenotype-first pooled CRISPR screening where live-cell function is measured directly before being linked to guide identity, transcriptome, morphology, and surface protein readouts.
The platform is delivered through the R3200 instrument (with onboard GPU and liquid handling robotics), proprietary flow cells pre-coated with extracellular matrix proteins and barcoded capture probes, the Cellanome Cloud software for visualization and analysis, and a suite of assays and workflows. The company sells to academic research institutions and biopharmaceutical companies via direct enterprise field sales, offering both instrument purchase and full-service CRISPR screening options. Cellanome is headquartered in Foster City, California, with additional offices in San Diego and Singapore, and has raised over $200 million from investors including 8VC, DFJ Growth, Premji Invest, and Wing Venture Capital.
Named customers and collaborators span UCSF (Matt Spitzer, Olaia Vila, and Camilla Valente labs), the Salk Institute (Joe Ecker and James Walker labs), and the Mayo Clinic (Annarita Scaramozza lab), with applications in tumor-immune interaction studies, neurobiology, aging and senescence, and immuno-oncology. Leadership includes CEO Omead Ostadan, CSO Gary Schroth, Co-founder Mostafa Ronaghi, Chairman Jay Flatley (former Illumina CEO), and board member Rowan Chapman. Revenue is not publicly disclosed, and pricing is quote-based for both platform purchase and service engagements.
Cellanome firmographics
Firmographics- Name
- Cellanome
- Legal name
- Cellanome, Inc.
- Website
- https://cellanome.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Cellanome is a private biotech that sells the R3200 Platform—an integrated system combining proprietary CellCage™ hydrogel enclosures, live-cell imaging, and single-cell transcriptomics—to academic labs and biopharmaceutical companies for multimodal cell analysis across immunology, oncology, neurobiology, and aging research.
- Ownership category
- akta.pro rank
Cellanome industry classification
Industry- Product category
- Single-Cell Analysis Instruments
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Services-Commercial Physical & Biological Research (8731), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)
- akta.pro secondary industry
- In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)
Keywords
Where Cellanome is headquartered
LocationHeadquarters
- HQ city
- Redwood City
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Cellanome business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- R3200 Platform Hardware Sales: Sale of the R3200 instrument system - an integrated platform combining instrumentation, flow cells, and software. Customers can purchase the platform and run workflows in their own labs.
- Flow Cells and Consumables: Proprietary flow cells with CellCage™ technology and consumables for running experiments on the R3200 platform.
- CRISPR Screening Services: Cellanome-run service lab can run CRISPR screens end-to-end for customers. Optional deeper analysis packages available for ranking perturbations and connecting phenotypic hits to transcriptomic programs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Platform purchase or service model |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Cellanome product offering
Product offeringCore offering
Cellanome develops and sells the R3200 Platform, an integrated live-cell analysis system that combines proprietary CellCage hydrogel microenvironments, automated fluorescent live-cell imaging, and single-cell transcriptomics. The platform enables researchers to track cellular behavior, morphology, and gene expression from the same individual cells over time. The company also operates a service lab that runs CRISPR screening experiments end-to-end for customers.
Product overview
Cellanome offers the R3200 Platform as its core unified product, which integrates four main components: the R3200 Instrument, Flow Cells, Assays & Workflows, and the Cellanome Cloud Platform. At the foundation of the platform is CellCage Technology—biocompatible, programmable hydrogel micro-environments that create custom enclosures around individual cells or small ensembles. This technology enables long-term live-cell culture, time-lapse imaging, perturbation, and single-cell transcriptomics all within the same experimental workflow. The platform is designed for applications across immunology, oncology, neuroscience, and aging research, supporting both phenotype-first CRISPR screening and multimodal single-cell analysis.
Differentiator
Problem solved
Functional benefit
Brands
- CellCage: Proprietary technology enabling customizable, biocompatible enclosures for single cells that support living cells in controlled microenvironments for culture, perturbation, and measurement of cell-cell interactions.
- CellCage Enclosures (CCEs)
- R3200 Platform
- Perturb-LINK
Products and services
- R3200 Platform Cellanome's flagship integrated live-cell analysis system combining instrumentation, flow cells, assays, and cloud software. Tracks live cells over time via time-lapse imaging while maintaining them in CellCage enclosures, then recovers single-cell transcriptomes from the same cells, linking behavioral history to molecular state.
- CellCage Technology Foundational proprietary technology consisting of biocompatible, light-guided hydrogel microenvironments that form customizable enclosures around selected cells. Preserves native morphology and supports culturing, time-lapse imaging, perturbation, and sequencing within a unified workflow.
- Cellanome Cloud Platform Cloud-based software component of the R3200 Platform providing experiment planning, time-course image visualization, and results linking across experimental timepoints.
- Flow Cells Programmable flow cells that serve as the foundation for CellCage enclosure formation. Pre-coated with fibronectin, PLO-laminin, or other extracellular matrix proteins to support adherent cell attachment and growth, with barcoded capture probes for transcriptomic profiling.
- Assays & Workflows Pre-configured experimental workflows and assay capabilities including morphology analysis, secretion profiling, transcriptomics, cell-cell interaction studies, CRISPR screening, and time-resolved functional readouts supporting both endpoint and longitudinal designs.
- CRISPR Screening Services Cellanome-run service lab that runs CRISPR screens end-to-end for customers, with optional deeper analysis packages available for ranking perturbations and connecting phenotypic hits to transcriptomic programs.
Quantifiable outcome
- Platform generates 5,000+ individual enclosures per lane, each generating independent time-lapse imaging and transcriptomic data
- +1 more outcomes
Companies that use Cellanome
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
Cellanome technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
Cellanome partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and secondary.
- UCSF (Dr. Matt Spitzer Lab)coreEarly collaborator during platform development. Lab uses Cellanome R3200 for cell-extrinsic CRISPR screening to study tumor-induced immune dysfunction. Dr. Spitzer describes collaboration as 'never had such a productive and close-knit collaborative interaction with a new technology company.'
- Salk Institute for Biological StudiescoreMultiple research collaborations including Joe Ecker Lab (multimodal single-cell analysis) and James Walker Lab (protoplast physiology and transcriptomics). Researchers present findings at conferences using Cellanome platform.
- Mayo ClinicsecondaryCollaboration with Mayo Clinic staff scientist Dr. Annarita Scaramozza on identifying subsets of senescent cells using platform capabilities for multi-modal analysis.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
Cellanome competitors and assessment
Company assessmentDirect peers
- 10x Genomics: 10x Genomics is the dominant single-cell analysis platform company (Chromium, Visium, Xenium). Cellanome directly competes by offering a complementary multimodal live-cell + transcriptomics workflow where 10x primarily provides endpoint single-cell assays. Both target academic and biopharma research customers.
- Bruker Cellular Analysis (formerly Berkeley Lights): Berkeley Lights (acquired by Bruker) developed the Beacon platform for live-cell functional screening and analysis using optoelectronic chips. Most directly comparable to Cellanome in combining live-cell imaging with downstream molecular readouts, though Cellanome's CellCage hydrogel approach is technologically distinct.
- Standard BioTools (formerly Fluidigm): Standard BioTools offers mass cytometry and microfluidic single-cell analysis instruments (Hyperion, CyTOF, Biomark). Competes with Cellanome in serving immunology and cell biology researchers needing high-dimensional single-cell data, though with different underlying technology platforms.
Emerging players
- Mission Bio: Mission Bio provides single-cell multi-omics for genomics and proteomics (Tapestri platform). An emerging player with partial overlap to Cellanome's single-cell transcriptomics and CRISPR screening capabilities, but focused more on DNA/genomics rather than live-cell phenotyping.
- Parse Biosciences: Parse Biosciences offers scalable single-cell RNA sequencing (Evercode). Competes in the single-cell transcriptomics space with Cellanome but at a different price point and scale, without live-cell imaging or functional screening capabilities.
- Takara Bio: Takara Bio offers single-cell genomics solutions (SMART-seq, ICELL8) and molecular biology reagents. Competes with Cellanome in single-cell transcriptomics reagent and instrument markets, particularly in academic research settings.
Broad incumbents
- Sartorius: Sartorius is a major bioprocessing and cell analysis tools provider serving pharma and academic customers with a broad portfolio including cell line development and live-cell analysis. Overlaps with Cellanome in cell biology applications but as a much broader incumbent rather than a focused specialist.
- Becton Dickinson (BD Biosciences): BD Biosciences is a major life science tools provider with flow cytometry, cell sorting, and single-cell analysis instruments (FACSDiscover, BD CellView). Overlaps with Cellanome in immunology and cell biology research, but as a broad incumbent with much larger scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Cellanome social profiles
Digital presenceCellanome financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cellanome leadership team
Management profileNumber of profiles
Profiles9 records
Cellanome funding detail
Funding detailFunding overview
Funding rounds5 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cellanome M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cellanome
What does Cellanome do?
Cellanome develops and sells the R3200 Platform, an integrated live-cell analysis system that combines proprietary CellCage hydrogel microenvironments, automated fluorescent live-cell imaging, and single-cell transcriptomics. The platform enables researchers to track cellular behavior, morphology, and gene expression from the same individual cells over time. The company also operates a service lab that runs CRISPR screening experiments end-to-end for customers.
Is Cellanome a public or private company?
Cellanome is a private company. It is classified as venture growth investor backed and is currently operating.
When was Cellanome founded?
Cellanome was founded in 2020. It employs 51 to 100 people.
Where is Cellanome based?
Cellanome is headquartered in Redwood City, United States, in the North America region.
How does Cellanome make money?
Three revenue lines are on record. R3200 Platform Hardware Sales are the primary driver. The others are flow Cells and Consumables and CRISPR Screening Services.
Who are Cellanome's main competitors?
Direct peers on record are 10x Genomics, Bruker Cellular Analysis (formerly Berkeley Lights) and Standard BioTools (formerly Fluidigm). Emerging players are Mission Bio, Parse Biosciences and Takara Bio. Broad incumbents are Sartorius and Becton Dickinson (BD Biosciences).
Does Cellanome have an API?
No public API is recorded for Cellanome.
What industry is Cellanome in?
Cellanome's product category is Single-Cell Analysis Instruments. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development), with a secondary code of HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems). Its NAICS code is 541714 and its SIC code is 8731.